[Combined treatment with fusion inhibitor. HIV-1 viruses under control longer].
D044966:Anti-Retroviral Agents / Q000009:adverse effects; D018791:CD4 Lymphocyte Count; D017326:Clinical Trials, Phase III as Topic; D004359:Drug Therapy, Combination; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000008:administration & dosage*; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D010446:Peptide Fragments / Q000008:administration & dosage*; D019562:Viral Load
D044966:Anti-Retroviral Agents; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide
Durch zusätzliche Behandlung mit Fusionshemmer. HI-Viren länger unter Kontrolle.